Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial
- Arvinas price target lowered to $19 from $28 at Citi
- Arvinas Holding: Positive Earnings Call Highlights Growth
- Arvinas Holding Faces Legal Risks Amid Stock Price Volatility
- Arvinas Holding Company: Strategic Advancements and Strong Financial Position Drive ‘Buy’ Rating